Contact Congress about S. 4066: Safeguarding Women from Chemical Abortion Act

Mifepristone could no longer have federal approval for ending a pregnancy inside the uterus. The bill would also let people sue the drug maker for certain physical or mental health harms tied to the drug.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Safeguarding Women from Chemical Abortion Act is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest action on S. 4066: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Who this affects: This bill mainly affects people seeking medication abortion, health care providers, and companies that make mifepristone. It could change whether the drug is available for ending pregnancies in places where it is now used. It would also give injured people a new federal way to sue manufacturers.

Why this matters: This bill could change access to a common medication used for abortion. It would remove federal approval for that use instead of leaving the decision to the usual Food and Drug Administration drug review process. It could also increase lawsuits against manufacturers because the new claim covers both bodily injury and mental health harm. Courts would have to decide how much connection is enough when harm is only partly tied to the drug.

Key provisions in S. 4066

• After 14 days, federal approval for using mifepristone to end a pregnancy inside the uterus would be treated as withdrawn. This would also cover generic versions that rely on mifepristone as the reference drug for that same use.
• Shipping or bringing these drugs across state lines for that abortion use would break the Federal Food, Drug, and Cosmetic Act, the main federal drug safety law.
• Mifepristone would count as wrongly labeled if its label says it can be used to end a pregnancy inside the uterus. This applies whether the label says to use it alone or with another drug, and it would trigger existing federal mislabeling enforcement rules.
• A covered entity means any person or business that makes the covered medication to be shipped or sold across state lines.
• Manufacturers could face federal lawsuits from people who suffer bodily injury or mental health harm partly or fully tied to using the covered medication.

How Modern Action helps you take action on S. 4066

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 4066

What is S. 4066?

Mifepristone could no longer have federal approval for ending a pregnancy inside the uterus. The bill would also let people sue the drug maker for certain physical or mental health harms tied to the drug.

How do I support or oppose S. 4066?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 4066?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain S. 4066 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.